基于Als1p重组N端结构域的抗念珠菌疫苗对播散性念珠菌病具有广泛的活性。
The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.
作者信息
Ibrahim Ashraf S, Spellberg Brad J, Avanesian Valentina, Fu Yue, Edwards John E
机构信息
Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502, USA.
出版信息
Infect Immun. 2006 May;74(5):3039-41. doi: 10.1128/IAI.74.5.3039-3041.2006.
Abstract
We have previously shown that vaccination with a vaccine based on the recombinant N-terminal domain of Als1p (rAls1p-N) protected BALB/c mice against disseminated infection caused by a single strain of Candida albicans (A. S. Ibrahim, B. J. Spellberg, V. Avenissian, Y. Fu, S. G. Filler, and J. E. Edwards, Jr., Infect. Immun. 73:999-1005, 2005, and B. J. Spellberg, A. S. Ibrahim, V. Avenissian, S. G. Filler, C. Myers, Y. Fu, and J. E. Edwards, Jr., Infect. Immun. 73:6191-6193, 2005). Here we show that the rAls1p-N vaccine also improves survival of outbred mice from disseminated candidiasis and that it is active against multiple virulent strains of C. albicans and non-C. albicans spp.
摘要
我们之前已经表明，用基于Als1p重组N端结构域的疫苗（rAls1p-N）对BALB/c小鼠进行免疫接种，可保护其免受由单一白色念珠菌菌株引起的播散性感染（A.S.易卜拉欣、B.J.斯佩尔伯格、V.阿韦尼西安、Y.傅、S.G.菲勒和J.E.爱德华兹，《感染与免疫》73:999-1005，2005年；以及B.J.斯佩尔伯格、A.S.易卜拉欣、V.阿韦尼西安、S.G.菲勒、C.迈尔斯、Y.傅和J.E.爱德华兹，《感染与免疫》73:6191-6193，2005年）。在此我们表明，rAls1p-N疫苗还可提高远交系小鼠从播散性念珠菌病中的存活率，并且它对多种白色念珠菌和非白色念珠菌的毒力菌株均有活性。
相似文献
1
The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.基于Als1p重组N端结构域的抗念珠菌疫苗对播散性念珠菌病具有广泛的活性。
Infect Immun. 2006 May;74(5):3039-41. doi: 10.1128/IAI.74.5.3039-3041.2006.
2
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.由Als1p重组N端组成的抗白色念珠菌疫苗可减轻免疫功能正常和免疫功能低下小鼠的真菌负荷并提高其存活率。
Infect Immun. 2005 Sep;73(9):6191-3. doi: 10.1128/IAI.73.9.6191-6193.2005.
3
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.抗念珠菌rAls3p-N或rAls1p-N疫苗对播散性和黏膜念珠菌病的疗效。
J Infect Dis. 2006 Jul 15;194(2):256-60. doi: 10.1086/504691. Epub 2006 Jun 6.
4
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.用Als1p重组N端结构域进行疫苗接种，通过增强细胞介导而非体液免疫，提高小鼠播散性念珠菌病的存活率。
Infect Immun. 2005 Feb;73(2):999-1005. doi: 10.1128/IAI.73.2.999-1005.2005.
5
Liposomal Fba and Met6 peptide vaccination protects mice from disseminated candidiasis.脂质体 Fba 和 Met6 肽疫苗可保护小鼠免受播散性念珠菌病的侵害。
mSphere. 2024 Jul 30;9(7):e0018924. doi: 10.1128/msphere.00189-24. Epub 2024 Jun 21.
6
Vaccination with Secreted Aspartyl Proteinase 2 Protein from Can Enhance Survival of Mice during -Mediated Systemic Candidiasis.分泌天门冬氨酸蛋白酶 2 蛋白疫苗可提高 - 介导系统性念珠菌病小鼠的存活率。
Infect Immun. 2020 Sep 18;88(10). doi: 10.1128/IAI.00312-20.
7
Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis.rHyr1p-N 的主动和被动免疫可保护小鼠免受血源性播散性念珠菌病的侵害。
PLoS One. 2011;6(10):e25909. doi: 10.1371/journal.pone.0025909. Epub 2011 Oct 10.
8
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.新城疫病毒-3 通过 T 细胞和 B 细胞免疫应答保护小鼠免受阴道念珠菌病的侵害。
Vaccine. 2013 Nov 12;31(47):5549-56. doi: 10.1016/j.vaccine.2013.09.016. Epub 2013 Sep 21.
9
Vaccination with Recombinant Non-transmembrane Domain of Protein Mannosyltransferase 4 Improves Survival during Murine Disseminated Candidiasis.用蛋白甘露糖基转移酶4的重组非跨膜结构域进行疫苗接种可提高小鼠播散性念珠菌病的存活率。
Biol Pharm Bull. 2015;38(11):1779-87. doi: 10.1248/bpb.b15-00475. Epub 2015 Aug 11.
10
Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine.播散性光滑念珠菌和热带念珠菌感染的鼠模型中免疫抑制的作用及一种合成肽疫苗的应用。
Med Mycol. 2019 Aug 1;57(6):745-756. doi: 10.1093/mmy/myy122.
引用本文的文献
1
Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.用于侵袭性念珠菌感染的下一代白色念珠菌重组Als3p和Hyr1p双抗原疫苗。
Res Sq. 2025 Sep 5:rs.3.rs-7270678. doi: 10.21203/rs.3.rs-7270678/v1.
2
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.宿主-微生物相互作用模式在急性和复发性外阴阴道念珠菌病中的作用。
Cell Host Microbe. 2024 Oct 9;32(10):1654-1667. doi: 10.1016/j.chom.2024.08.018.
3
Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.真菌疫苗和佐剂：揭示宿主与真菌相互作用的工具。
Arch Microbiol. 2024 Jun 8;206(7):293. doi: 10.1007/s00203-024-04010-7.
4
Advancements and challenges in antifungal therapeutic development.抗真菌治疗药物研发的进展与挑战。
Clin Microbiol Rev. 2024 Mar 14;37(1):e0014223. doi: 10.1128/cmr.00142-23. Epub 2024 Jan 31.
5
Advancing Vaccine Strategies against Infections: Exploring New Frontiers.推进针对感染的疫苗策略：探索新领域。
Vaccines (Basel). 2023 Oct 29;11(11):1658. doi: 10.3390/vaccines11111658.
6
Antibodies to Combat Fungal Infections: Development Strategies and Progress.对抗真菌感染的抗体：研发策略与进展
Microorganisms. 2023 Mar 6;11(3):671. doi: 10.3390/microorganisms11030671.
7
Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant .抗Hyr1p单克隆抗体对多重耐药性所致系统性念珠菌病的保护效力
J Fungi (Basel). 2023 Jan 12;9(1):103. doi: 10.3390/jof9010103.
8
Vaccines against candidiasis: Status, challenges and emerging opportunity.抗念珠菌疫苗：现状、挑战和新机遇。
Front Cell Infect Microbiol. 2022 Aug 18;12:1002406. doi: 10.3389/fcimb.2022.1002406. eCollection 2022.
9
Antibodies targeting Als3 and Hyr1 antigens protect neonatal mice from candidiasis.针对 Als3 和 Hyr1 抗原的抗体可保护新生小鼠免受念珠菌病的侵害。
Front Immunol. 2022 Jul 22;13:925821. doi: 10.3389/fimmu.2022.925821. eCollection 2022.
10
Bacterial-fungal interactions and their impact on microbial pathogenesis.细菌-真菌相互作用及其对微生物发病机制的影响。
Mol Ecol. 2023 May;32(10):2565-2581. doi: 10.1111/mec.16411. Epub 2022 Mar 14.
本文引用的文献
1
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.由Als1p重组N端组成的抗白色念珠菌疫苗可减轻免疫功能正常和免疫功能低下小鼠的真菌负荷并提高其存活率。
Infect Immun. 2005 Sep;73(9):6191-3. doi: 10.1128/IAI.73.9.6191-6193.2005.
2
Mice with disseminated candidiasis die of progressive sepsis.患有播散性念珠菌病的小鼠死于进行性败血症。
J Infect Dis. 2005 Jul 15;192(2):336-43. doi: 10.1086/430952. Epub 2005 Jun 3.
3
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.用Als1p重组N端结构域进行疫苗接种，通过增强细胞介导而非体液免疫，提高小鼠播散性念珠菌病的存活率。
Infect Immun. 2005 Feb;73(2):999-1005. doi: 10.1128/IAI.73.2.999-1005.2005.
4
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.美国医院的医院获得性血流感染：来自一项全国性前瞻性监测研究的24179例病例分析。
Clin Infect Dis. 2004 Aug 1;39(3):309-17. doi: 10.1086/421946. Epub 2004 Jul 15.
5
Functional and structural diversity in the Als protein family of Candida albicans.白色念珠菌Als蛋白家族的功能和结构多样性
J Biol Chem. 2004 Jul 16;279(29):30480-9. doi: 10.1074/jbc.M401929200. Epub 2004 May 5.
6
Attributable mortality of nosocomial candidemia, revisited.医院念珠菌血症的归因死亡率，再探讨。
Clin Infect Dis. 2003 Nov 1;37(9):1172-7. doi: 10.1086/378745. Epub 2003 Oct 8.
7
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).通过致病微生物分析严重脓毒症中的全身宿主反应及重组人活化蛋白C的治疗效果
Clin Infect Dis. 2003 Jul 1;37(1):50-8. doi: 10.1086/375593. Epub 2003 Jun 24.
8
Modular domain structure in the Candida glabrata adhesin Epa1p, a beta1,6 glucan-cross-linked cell wall protein.光滑念珠菌黏附素Epa1p中的模块化结构域，一种β1,6-葡聚糖交联的细胞壁蛋白。
Mol Microbiol. 2002 Oct;46(2):479-92. doi: 10.1046/j.1365-2958.2002.03166.x.
9
The Pathophysiology and Treatment of Candida Sepsis.念珠菌败血症的病理生理学与治疗
Curr Infect Dis Rep. 2002 Oct;4(5):387-399. doi: 10.1007/s11908-002-0005-3.
10
Characterization of agglutinin-like sequence genes from non-albicans Candida and phylogenetic analysis of the ALS family.非白念珠菌凝集素样序列基因的特征分析及ALS家族的系统发育分析
Genetics. 2001 Apr;157(4):1555-67. doi: 10.1093/genetics/157.4.1555.
Zotero 插件